Illumina became a genomics juggernaut by developing machines that could read large amounts of DNA accurately and quickly. But the companyâs betting the next phase of its growth will be accelerated by helping customers better understand genetic data and apply it to drug development.
The San Diego firm took a step in that direction on Tuesday, when it unveiled what it says will be the worldâs largest dataset of its kind, the Billion Cell Atlas. The atlas is based on the results of turning on or off genes across 200 cell lines, including lines used to study heart disease, neurologic disorders, immune conditions, and cancer.
Data on how these genetic perturbations affect cells could in principle help drug companies validate drug targets or create âvirtual cells,â artificial intelligence-powered models of cell behavior. Thus far, Illumina has generated data from about 150 million cells and expects to reach a billion by the end of the year. The companyâs already offering the atlas as a resource for pharmaceutical companies, with Merck, AstraZeneca, and Eli Lilly as its first customers. Several others have expressed interest, too, according to CEO Jacob Thaysen.Continue to STAT+ to read the full storyâŚ